Indivior Pharmaceuticals, Inc. Earnings Per Share (Diluted)
Indivior Pharmaceuticals, Inc. (INDV) reported Earnings Per Share (Diluted) of $0.98 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was $0.98, a 600.00% increase year-over-year.
- Indivior Pharmaceuticals, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was $0.69, a 81.58% increase year-over-year.
- Indivior Pharmaceuticals, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was $0.78, a 382.01% increase year-over-year.
- Indivior Pharmaceuticals, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was $0.33, a 106.25% increase year-over-year.
- Indivior Pharmaceuticals, Inc. earnings per share, diluted for fiscal 2025 was $1.64, a 3180.00% increase from fiscal 2024.
- Indivior Pharmaceuticals, Inc. earnings per share, diluted for fiscal 2024 was $0.05.
- Indivior Pharmaceuticals, Inc. earnings per share, diluted for fiscal 2023 was -$0.92.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.98 10-Q · filed 2026-08-03 | $1.67 10-Q · filed 2026-08-03 | $2.45 derived: net income ÷ weighted average shares · filed 2026-08-03 | $2.77 derived: net income ÷ weighted average shares · filed 2026-08-03 | |
| 2026-03-31 | $0.69 10-Q · filed 2026-04-30 | $1.47 derived: net income ÷ weighted average shares · filed 2026-08-03 | $1.80 derived: net income ÷ weighted average shares · filed 2026-08-03 | $1.95 derived: net income ÷ weighted average shares · filed 2026-08-03 | |
| 2025-12-31 | $0.78 derived: net income ÷ weighted average shares · filed 2026-02-26 | $1.11 derived: net income ÷ weighted average shares · filed 2026-02-26 | $1.26 derived: net income ÷ weighted average shares · filed 2026-08-03 | $1.64 10-K · filed 2026-02-26 | |
| 2025-09-30 | $0.33 10-Q · filed 2025-10-30 | $0.47 derived: net income ÷ weighted average shares · filed 2026-08-03 | $0.85 10-Q · filed 2025-10-30 | $1.00 derived: net income ÷ weighted average shares · filed 2026-08-03 | |
| 2025-06-30 | $0.14 10-Q · filed 2026-08-03 | $0.52 10-Q · filed 2026-08-03 | $0.68 derived: net income ÷ weighted average shares · filed 2026-08-03 | $0.84 derived: net income ÷ weighted average shares · filed 2026-08-03 | |
| 2025-03-31 | $0.38 10-Q · filed 2026-04-30 | $0.53 derived: net income ÷ weighted average shares · filed 2026-08-03 | $0.70 derived: net income ÷ weighted average shares · filed 2026-08-03 | -$0.05 derived: net income ÷ weighted average shares · filed 2026-08-03 | |
| 2024-12-31 | $0.16 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.33 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.41 derived: net income ÷ weighted average shares · filed 2026-02-26 | $0.05 10-K · filed 2026-02-26 | $0.02 10-K · filed 2025-03-03 |
| 2024-09-30 | $0.16 10-Q · filed 2025-10-30 | -$0.56 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.11 10-Q · filed 2025-10-30 | ||
| 2024-06-30 | -$0.72 10-Q · filed 2025-07-31 | -$0.27 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | $0.45 10-Q · filed 2025-05-01 | ||||
| 2023-12-31 | -$0.92 10-K · filed 2026-02-26 | -$0.94 10-K · filed 2025-03-03 | |||
| 2022-12-31 | -$0.30 10-Q · filed 2025-10-30 | -$0.32 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |